A Clinical Trial of Infliximab for Uveitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-08-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis

NCT01603355

Juvenile Idiopathic Arthritis Associated Uveitis

TERMINATED PHASE1/PHASE2

Leflunomide to Treat Uveitis

NCT00001863

Uveitis

COMPLETED PHASE2

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema

NCT00958906

Uveitic Macular Edema Intraocular Inflammation

WITHDRAWN PHASE1/PHASE2

Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

NCT00525902

Uveitis

COMPLETED PHASE2

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

NCT06085079

Uveitis, Posterior Uveitis, Anterior Uveitis, Intermediate +1 more

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveitis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remicade (infliximab)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The study group will include patients suffering from treatment-resistant vision-threatening uveitis who attend the Uveitis Clinic at Casey Eye Institute.
2. We plan to enroll 32 patients.

Exclusion Criteria

1. Patients with ocular or systemic infection.
2. Patients with the subtype of uveitis termed pars planitis who have MRI scan evidence of demyelination. There is a theoretical risk of adverse outcome of TNF-alpha inhibition on the clinical course of multiple sclerosis. Patients who suffer from pars planitis are at increased risk of developing multiple sclerosis.
3. Children under the age of 9.
4. Patients with known sensitivity to mouse proteins. Remicade is a chimeric protein with human and murine components.
5. Patients with history of cancer (exception- skin cancers which are curatively resected), organ transplantation (exception- cornea), recent drug or alcohol addiction, or inability to keep appointments.
6. Patients with other serious systemic diseases that could interfere with participation in the study.
7. It is specifically noted that pregnant women and nursing mothers will be excluded from this study.

Minimum Eligible Age

9 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No